Umbilical Cord-derived MSC for COVID-19 Patients With ARDS
ARDS · COVID-19
Enrolment: 24 · Results not recorded
Loading the evidence…
Biologic · ChEMBL not queried: genetically modified cell therapy, no chemical entity. CLASS/MODALITY-LEVEL translation only. NO human trial uses ECSOD-transduced cells; all recorded trials give UNMODIFIED umbilical cord MSC in acute lung injury or ARDS, which is the matching indication. NCT04452097 is WITHDRAWN at 0 enrolment and two further trials have not yet started recruiting.
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
ARDS · COVID-19
Enrolment: 24 · Results not recorded
Acute Respiratory Distress Syndrome
Enrolment: 129 · Results not recorded
Acute Respiratory Distress Syndrome
Enrolment: 36 · Results not recorded
Acute Respiratory Distress Syndrome
Enrolment: 60 · Results not recorded
COVID-19 · ARDS
Enrolment: 0 · Results not recorded
Acute Respiratory Distress Syndrome
Enrolment: 26 · Results not recorded
1 studies reported at therapy level; 1 evidence entries itemised.
Model: Acute radiation syndrome after sub-lethal irradiation
Systemically administered ECSOD-modified umbilical cord mesenchymal stromal cells protected mice from sub-lethal irradiation and improved survival by promoting multilineage haematopoietic recovery, associated with reduced superoxide and apoptosis.
Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.